RAC (ASX) Accent Therapeutics: What can we learn?

Originally posted by RaceOncology: ↑

Rather than continuing to roll around in the mud with the trolls I thought we should take a look at other biotechs in RNA space and what they are doing. Accent Therapeutics is a private, preclinical biotech based in Lexington (Boston) working on developing drugs in the RNA modification space (i.e. FTO). Their blurb sums them up well.

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of RNA modification. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, the Company aims to translate extraordinary science into life-changing therapies for patients.

So why is Accent of interest to the RAC shareholders? The answer lies in the deal they signed with AstraZenica in June for US$1.1 billion. Remember that Accent are only at the preclinical stage and they have not yet treated a single patient.

Lexington, MA, June 4, 2020 – Accent Therapeutics and AstraZeneca (LSE/STO/NYSE: AZN) will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. The collaboration combines Accent’s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s industry leading expertise in oncology.

Inhibition of RMPs is a new approach for addressing RNA pathobiology by targeting proteins that control many aspects of RNA biology. This class of targets represents a vast field of potentially important targets for cancer and other diseases.

José Baselga, Executive Vice President, Oncology R&D, AstraZeneca said: “The promise of RMP inhibition is a compelling area of exploration for AstraZeneca. With this collaboration, we will seek to identify novel targets and unlock the full potential of our medicines. We believe that the Accent team’s expertise in RNA-modifying protein biology and drug discovery complements AstraZeneca’s extensive research and development portfolio.”

Shakti Narayan, Chief Executive Officer, Accent Therapeutics said: “This collaboration leverages both AstraZeneca’s vast cancer expertise and resources and Accent’s rich pipeline of RMP therapeutic programs to bring new and potentially life-changing medicines to patients. This collaborative effort will enable us to rapidly advance and achieve the rich therapeutic potential of these exciting programs.”

Under the terms of the collaboration agreement, Accent will be responsible for research and development activities for a nominated preclinical program through to the end of Phase I clinical trials. Following completion of Phase I, AstraZeneca will lead development and commercialization activities for the nominated program, with Accent having the option to jointly develop and commercialize with AstraZeneca in the US. AstraZeneca will also have the exclusive option to license worldwide rights to two further preclinical discovery programs, for which Accent will conduct certain preclinical activities.

Accent will receive an upfront payment of $55 million and, in the event that Accent elects to jointly develop the nominated program, is eligible to receive up to $1.1 billion in additional success-based payments across all programs in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Accent opts into co-developing and co-commercializing the nominated program, profits and losses will be split in the US.

https://www.accenttx.com/press-releases/accent-therapeutics-and-astrazeneca-to-discover-and-develop-novel-cancer-therapeutics-in-new-collaboration/

Expand

Worth rereading this for all those with itchy feet.

No.	Vol.	Price($)
1	500	$1.81

No.

Vol.

Price($)

500

$1.81

Price($)	Vol.	No.
$1.83	641	1

Price($)

Vol.

No.

$1.83

641

No.	Vol.	Price($)
1	500	1.810
3	7009	1.790
1	450	1.780
2	16392	1.770
2	1018	1.765

No.

Vol.

Price($)

500

1.810

7009

1.790

450

1.780

16392

1.770

1018

1.765

Price($)	Vol.	No.
1.830	558	1
1.840	4000	2
1.845	2746	1
1.860	1000	1
1.870	1200	1

Price($)

Vol.

No.

1.830

558

1.840

4000

1.845

2746

1.860

1000

1.870

1200

(20min delay)
Last $1.83		Change 0.020(1.11%)		Mkt cap ! $310.7M

Open	High	Low	Value	Volume
$1.81	$1.83	$1.79	$142.0K	78.77K

Worth rereading this for all those with itchy feet.

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Worth rereading this for all those with itchy feet.

Top Stories

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News